Reflux Esophagitis (Gastroesophageal Reflux Disease) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 88.89% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Reflux Esophagitis (Gastroesophageal Reflux Disease) compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Reflux Esophagitis (Gastroesophageal Reflux Disease) overview
Gastroesophageal reflux disease (GERD) refers to a condition where the liquid content of the stomach refluxes into the esophagus. It is a chronic condition. The symptoms of GERD are nausea, heartburn, and vomiting. The predisposing factors include eating large meals, which can cause the lower esophageal sphincter (LES) to open inappropriately, as well as obesity, pregnancy, greasy food, and certain drugs.
For a complete picture of PTSR and LoA scores for drugs in Reflux Esophagitis (Gastroesophageal Reflux Disease), buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.